Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Capital Expenditures for 12 consecutive years, with -$390000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 126.68% to -$390000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $467000.0, a 68.06% decrease, with the full-year FY2025 number at $467000.0, down 68.06% from a year prior.
  • Capital Expenditures was -$390000.0 for Q4 2025 at Madrigal Pharmaceuticals, down from $857000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2024 to a low of -$488000.0 in Q3 2024.
  • A 5-year average of $213000.0 and a median of $60500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 5050.0% in 2022, then crashed 243.95% in 2024.
  • Madrigal Pharmaceuticals' Capital Expenditures stood at $113000.0 in 2021, then tumbled by 74.34% to $29000.0 in 2022, then soared by 3472.41% to $1.0 million in 2023, then skyrocketed by 41.12% to $1.5 million in 2024, then plummeted by 126.68% to -$390000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Capital Expenditures are -$390000.0 (Q4 2025), $857000.0 (Q3 2025), and $1.5 million (Q4 2024).